Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals (RYTM) has scheduled a conference call and webcast for April 7, 2025, at 8:00 a.m. ET to present topline results from their Pivotal Phase 3 TRANSCEND trial. The trial evaluates setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.
The biopharmaceutical company, which focuses on rare neuroendocrine diseases, will make the webcast available under the 'Events and Presentations' section of their investor relations website. The recording will remain accessible for at least 30 days after the call.
Rhythm Pharmaceuticals (RYTM) ha programmato una conference call e un webcast per il 7 aprile 2025, alle 8:00 ET, per presentare i risultati preliminari del loro trial Pivotal Phase 3 TRANSCEND. Lo studio valuta setmelanotide, un agonista del recettore melanocortin-4 (MC4R), in pazienti con obesità ipotalamica acquisita.
La società biofarmaceutica, che si concentra su malattie neuroendocrine rare, renderà il webcast disponibile nella sezione 'Eventi e Presentazioni' del loro sito web per le relazioni con gli investitori. La registrazione rimarrà accessibile per almeno 30 giorni dopo la chiamata.
Rhythm Pharmaceuticals (RYTM) ha programado una conferencia telefónica y un webcast para el 7 de abril de 2025, a las 8:00 a.m. ET, para presentar los resultados preliminares de su ensayo Pivotal Phase 3 TRANSCEND. El ensayo evalúa setmelanotide, un agonista del receptor melanocortina-4 (MC4R), en pacientes con obesidad hipotalámica adquirida.
La empresa biofarmacéutica, que se centra en enfermedades neuroendocrinas raras, hará disponible el webcast en la sección 'Eventos y Presentaciones' de su sitio web de relaciones con inversores. La grabación permanecerá accesible durante al menos 30 días después de la llamada.
Rhythm Pharmaceuticals (RYTM)는 2025년 4월 7일 오전 8시 ET에 Pivotal Phase 3 TRANSCEND 시험의 주요 결과를 발표하기 위해 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 이 시험은 setmelanotide를 평가하며, 이는 획득된 시상하부 비만 환자에서의 멜라노코르틴-4 수용체(MC4R) 작용제입니다.
희귀 신경내분비 질환에 집중하는 이 생명공학 회사는 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션에서 웹캐스트를 제공할 예정입니다. 녹화는 통화 후 최소 30일 동안 접근할 수 있습니다.
Rhythm Pharmaceuticals (RYTM) a prévu une conférence téléphonique et un webinaire pour le 7 avril 2025 à 8h00 ET afin de présenter les résultats préliminaires de leur essai Pivotal Phase 3 TRANSCEND. L'essai évalue setmelanotide, un agoniste du récepteur mélanocortine-4 (MC4R), chez des patients souffrant d'obésité hypothalamique acquise.
L'entreprise biopharmaceutique, qui se concentre sur les maladies neuroendocrines rares, mettra le webinaire à disposition dans la section 'Événements et Présentations' de son site web pour les relations avec les investisseurs. L'enregistrement restera accessible pendant au moins 30 jours après l'appel.
Rhythm Pharmaceuticals (RYTM) hat eine Telefonkonferenz und einen Webcast für den 7. April 2025 um 8:00 Uhr ET angesetzt, um die vorläufigen Ergebnisse ihrer Pivotal Phase 3 TRANSCEND-Studie zu präsentieren. Die Studie bewertet setmelanotide, einen Agonisten des Melanocortin-4-Rezeptors (MC4R), bei Patienten mit erworbener hypothalamischer Fettleibigkeit.
Das biopharmazeutische Unternehmen, das sich auf seltene neuroendokrine Erkrankungen konzentriert, wird den Webcast im Bereich 'Veranstaltungen und Präsentationen' auf seiner Investor Relations-Website zur Verfügung stellen. Die Aufzeichnung bleibt mindestens 30 Tage nach dem Anruf zugänglich.
- None.
- None.
Company to host conference call on April 7 at 8 a.m. ET
BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the Pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.
Conference Call Information
Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Monday, April 7, to discuss these clinical data. Participants may register for the conference call here. A webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/. The archived webcast will be available on Rhythm Pharmaceuticals’ website approximately two hours after the conference call and will be available for at least 30 days following the call.
About the Phase 3 TRANSCEND Trial
The global, randomized, double-blind, placebo-controlled Phase 3 TRANSCEND trial evaluated the efficacy and safety of setmelanotide in patients with acquired hypothalamic obesity. A total of 120 patients age 4 years and older were randomized 2:1 to either a daily subcutaneous injection of setmelanotide or placebo. The primary endpoint was mean percent change in body mass index (BMI) from baseline after 52 weeks of treatment. Secondary endpoints are assessing daily hunger, hyperphagia (extreme unsatisfied drive to consume food), weight, quality of life and safety and tolerability. A supplemental cohort of 12 Japanese patients remains ongoing with completion and topline data anticipated in the first quarter of 2026.
About Acquired Hypothalamic Obesity
Acquired hypothalamic obesity is a rare form of obesity that occurs following damage to the hypothalamic region of the brain, which includes the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological functions such as hunger and weight regulation. Acquired hypothalamic obesity most frequently follows the growth or surgical removal of craniopharyngioma, astrocytoma or other rare brain tumors. Additional causes of injury may include traumatic brain injury, stroke, or inflammation due to infection. Patients experience accelerated weight gain, a reduction in energy expenditure, and hyperphagia (a chronic pathological condition characterized by insatiable hunger, impaired satiety, and persistent abnormal food-seeking behaviors) leading to severe obesity within six to 12 months following tumor resection or other injury.
Setmelanotide Indication
In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
- Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign
- Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
WARNINGS AND PRECAUTIONS
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.
Depression and Suicidal Ideation: Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.
Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New
Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥
USE IN SPECIFIC POPULATIONS
Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.
Please see the full Prescribing Information for additional Important Safety Information.
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our planned announcement and conference call regarding our pivotal Phase 3 TRANSCEND study evaluating setmelanotide for the treatment of acquired hypothalamic obesity; and the safety, efficacy, potential benefits of, and clinical design or progress of setmelanotide to treat patients with acquired hypothalamic obesity. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will”, “aim” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the ability to achieve necessary regulatory approvals, risks associated with data analysis and reporting, positive results from earlier clinical trials of setmelanotide may not be predictive of the results of later clinical trials of setmelanotide, interim, topline and preliminary data that we announced may change as more patient data become available, failure to identify and develop additional product candidates, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(949) 903-4750
sseapy@realchemistry.com
FAQ
When will Rhythm Pharmaceuticals (RYTM) announce the TRANSCEND trial results?
What is the purpose of RYTM's Phase 3 TRANSCEND trial?
How can investors access RYTM's TRANSCEND trial results presentation?
How long will the RYTM TRANSCEND trial webcast be available?
